为I/IIa期霍奇金淋巴瘤的放疗决策提供信息:使用放射剂量学建模预期寿命
该微模拟模型估计I/IIa期霍奇金淋巴瘤患者接受联合模式治疗或单纯化疗后的终生质量调整生命年。吸烟状态对最佳治疗选择影响很大:从不吸烟者几乎均从联合模式治疗获益,而当前吸烟者可从单纯化疗显著获益。
要点
- 从不吸烟者几乎均从联合模式治疗获益,不受年龄、性别和危及器官剂量影响。
- 当前吸烟者可从单纯化疗显著获益,最大获益为20岁男性当前吸烟者双侧颈部及全纵隔受累。
- 联合模式治疗在年轻患者、纳入未来健康贴现及从不吸烟者中更有利。
核心结论
- 吸烟状态对I/IIa期霍奇金淋巴瘤最佳治疗选择影响很大;从不吸烟者几乎均从联合模式治疗获益,而当前吸烟者可从单纯化疗显著获益。
研究设计与样本
- 微模拟模型,估计I/IIa期霍奇金淋巴瘤患者接受联合模式治疗或单纯化疗后的终生质量调整生命年。
- 联合模式治疗模型纳入乳腺癌、肺癌、冠心病和缺血性卒中风险。
- 比较 outcomes 在年龄、性别、吸烟状态和基于RAPID试验的代表性危及器官放射剂量不同的示例患者中进行。
- 分析分别在有和无3.5%未来健康贴现率下进行。
主要发现
- 联合模式治疗对几乎所有从不吸烟示例患者均更优,不受年龄、性别和危及器官剂量影响。
- 最大获益:20岁男性从不吸烟者单侧颈部病变,联合模式治疗获1.095(95% CI: 1.054-1.137)未贴现质量调整生命年增益。
- 当前吸烟者可大幅从单纯化疗获益;最大获益:20岁男性当前吸烟者双侧颈部及全纵隔受累,单纯化疗获3.500(95% CI: 3.400 to 3.600)未贴现质量调整生命年增益。
- 总体而言,患者越年轻、纳入未来健康贴现及从不吸烟者中,联合模式治疗更有利。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent randomized trials, omitting consolidative radiotherapy (RT) in early-stage Hodgkin lymphoma (ESHL) increased relapses. However, decades of follow-up are required to observe whether lower initial disease control is compensated by reduced risk of late effects. Extrapolation beyond trial follow-up is therefore necessary to inform current treatment decisions. To this end, we developed a microsimulation model to estimate lifetime quality-adjusted life years (QALYs) after combined modality treatment (CMT) or chemotherapy-alone for stage I/IIa ESHL. For CMT, the model included risks of breast and lung cancer, coronary heart disease, and ischemic stroke. Comparative outcomes were assessed for a clinically relevant range of example patients differing by age, sex, smoking status, and representative organs at risk (OAR) radiation doses informed by the RAPID trial. Analysis was performed with and without a 3.5% discount rate on future health. Smoking status had a large effect on optimal treatment choice. CMT was superior for nearly all never smoker example patients regardless of age, sex, and OAR doses. At a maximum, CMT produced a 1.095 (95% CI: 1.054-1.137) gain in undiscounted QALYs for a 20-year-old male never smoker with unilateral neck disease. In contrast, current smokers could substantially gain from chemotherapy-alone treatment. Again at a maximum, a 20-year-old male current smoker with bilateral neck and whole mediastinum involvement gained 3.500 (95% CI: 3.400 to 3.600) undiscounted QALYs with chemotherapy-alone treatment. Overall, CMT was more favorable the younger the patient, when future health discounting was included, and in never smokers.
引用
- Jones DA, Candio P, Shakir R, et al. Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry. Blood Adv. 2022. PMID: 34872107. doi:10.1182/bloodadvances.2021006254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。